化合物信息

ID:1098

基本信息
化学结构
MolImage
分子式
C₄₇H₅₁NO₁₄
分子量
853.90614
精确质量
853.33095532
电荷
0
InChI
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
InChIKey
RCINICONZNJXQF-MZXODVADSA-N
Canonic Smiles
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@@H]3[C@]([C@H]2[C@@H]([C@]2(C(C1=C(C)[C@@H](OC(=O)[C@@H]([C@H](c1ccccc1)NC(=O)c1ccccc1)O)C2)(C)C)O)OC(=O)c1ccccc1)(CO3)OC(=O)C
Isomeric Smiles
[C@H]1(OC(=O)c2ccccc2)[C@@H]2[C@@]3(CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@@H](C2=C([C@H](C[C@]1(O)C2(C)C)OC(=O)[C@@H]([C@H](c1ccccc1)NC(=O)c1ccccc1)O)C)OC(=O)C)C)O)OC(=O)C
计算属性
JChem
LogD (pH = 7.4)
3.54
LogD (pH = 5.5)
3.54
Log P
3.54
可自由旋转的化学键
14
质子供体
4
质子受体
10
里宾斯基五规则
false
Acid pKa
11.93
极化表面积
221.29
极化性
87.13
摩尔折射率
218.29
LOG S
-6.77
名称和标识
商标名
LipoPacOnxolAbraxanePaxceedVascular WrapTaxol ATaxolEpitaxolXoranePaxene
IUPAC标准名
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl benzoate (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
别名
7-EpitaxolABI-0077-epi-Taxol7-epi-PaclitaxelPaclitaxel7-EpipaclitaxelTaxol®NSC 125973YewtaxanOncoGel(-)-PaclitaxelPacliexTaxolAbraxaneOnxalGenaxolGenetaxylAnzataxPaclitaxelTaxol AtaxolTAXOL(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl esterPaclitaxel5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserineTaxol Apaclitaxel
IUPAC传统名
TAX taxol paclitaxel (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl benzoate (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
API名称
Paclitaxel
数据登录号
化合物性质
理化性质
疏水性(logP)
3
溶解度
Insoluble
Methanol
蒸汽压
< 1.12 x 10-7 Torr
熔点
213-223°C
214-216°C
外观
White Solid
Powder
药理学性质
生物利用度
6.5% (oral)
半衰期
5.8 hours
法定药品分级
Rx-only (US)
给药途径
iv
排泄
Fecal and urinary
妊娠期药物分类
D (US)
蛋白结合率
89 to 98%
代谢
Hepatic (CYP2C8 and CYP3A4)
生物活性机理
Interferes with the normal function of microtubule growth by hyper-stabilisation of their structure
Binds to the beta subunit of tubulin
安全信息
澳大利亚Hazchem
2X
MSDS下载
危险公开号 
R:25
RTECS编号
DA8340700
联合国危险货物包装类别(PG)
III
欧盟危险货物分类
T2
欧盟危险识别号(EUHIN)
6.1B
联合国危险货物等级
6.1
美国ERG指导号
154
欧盟危险性物质标志
有毒 有毒 (T)
保存条件
Room Temperature (15-30°C)
-20°C Freezer
安全公开号 
S:28-36/37/39-45-53
联合国危险货物编号
2811
产品相关信息
质检报告
纯度
>98%
95+%
应用领域
Antileukaemic and antineoplastic agent, esp. against melanoma and ovarian tumours
Use limited by low solubility and scarce availability of Taxus brevifolia bark
Biochemical tool extensively used to study cellular shape and function.
Also shown to be active against oomycete fungi
生物来源
Isol. from the stem bark of Taxus brevifolia and Taxus cuspidata (Taxaceae)
分子相关蛋白质
分子图谱
暂无数据
点击上传数据
描述信息
Drug Groups
approved
Description
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. [PubChem] ABI-007 (Abraxane) is the latest attempt to improve upon paclitaxel, one of the leading chemotherapy treatments. Both drugs contain the same active agent, but Abraxane is delivered by a nanoparticle technology that binds to albumin, a natural protein, rather than the toxic solvent known as Cremophor. It is thought that delivering paclitaxel with this technology will cause fewer hypersensitivity reactions and possibly lead to greater drug uptake in tumors.
Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast.
Pharmacology
Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Toxicity
Rat (ipr) LD50=32530 µg/kg. Symptoms of overdose include bone marrow suppression, peripheral neurotoxicity, and mucositis. Overdoses in pediatric patients may be associated with acute ethanol toxicity.
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic. In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6a-hydrox-ypaclitaxel by the cytochrome P450 isozyme CYP2C8; and to two minor metabolites, 3’-p-hydroxypaclitaxel and 6a, 3’-p-dihydroxypaclitaxel, by CYP3A4.
Absorption
I.V injected
Half Life
Average distribution half-life of 0.34 hours and an average elimination half-life of 5.8 hours.
Protein Binding
89%-98%
Elimination
In 5 patients administered a 225 or 250 mg/m2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine.
Distribution
* 227 to 688 L/m2
Clearance
* 21.7 L/h/m2 [Dose 135 mg/m2, infusion duration 24 h]
* 23.8 L/h/m2 [Dose 175 mg/m2, infusion duration 24 h]
* 7 L/h/m2 [Dose 135 mg/m2, infusion duration 3 h]
* 12.2 L/h/m2 [Dose 175 mg/m2, infusion duration 3 h]
References
• Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995 Feb 15;55(4):753-60. [Pubmed]
• Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325-7. [Pubmed]
• Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978 Aug;62(8):1219-22. [Pubmed]
• Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. [Pubmed]
• ABI 007. Drugs R D. 2004;5(3):155-9. [Pubmed]
• Gaitanis A, Staal S: Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 2010;624:385-92. [Pubmed]
External Links
• [Wikipedia]
• [RxList]
• [Drugs.com]
(Taxol?) From the Pacific Yew Tree Taxus brevifolia Antitumor agent which lowers the critical concentration for tubulin polymerization and reversibly binds to tubulin prohibiting depolymerization. Purity: >98%
An antineoplastic. Used in the study of structure and function of microtubles into tubulin. Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is a mitotic i
A tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia. It is a mitotic inhibitor used in cancer chemotherapy. Note that the use of the former generic name 'taxol' is now limited, as Taxol is a registered trade mark.
参考文献
PubChem文献
数据源提供
• Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325-7. Pubmed
• Gaitanis A, Staal S: Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 2010;624:385-92. Pubmed
• Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995 Feb 15;55(4):753-60. Pubmed
• Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. Pubmed
• ABI 007. Drugs R D. 2004;5(3):155-9. Pubmed
• Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978 Aug;62(8):1219-22. Pubmed
• Winkler, J.D. et al., Tetrahedron, 1992, 48, 6953, (rev)
• Kingston, D.G.I. et al., J. Nat. Prod., 1982, 45, 466-470, (2',7-di-Ac)
• Horwitz, S.B. et al., Ann. N.Y. Acad. Sci., 1986, 466, 733, (rev, pharmacol)
• Ojima, I. et al., Tetrahedron, 1992, 48, 6985, (synth)
• Wall, M.E., Chron. Drug Discovery, 1993, 3, 327, (rev)
• Kingston, D.G.I. et al., J. Nat. Prod., 1990, 53, 1; 802, (bibl, rev)
• Chmurny, G.N. et al., J. Nat. Prod., 1992, 55, 414, (pmr, cmr)
• Wani, M.S. et al., J.A.C.S., 1971, 93, 2325, (isol, nmr, ms, ir, uv)
• Young, D.H. et al., Experientia, 1992, 48, 882, (antifungal activity)
• Hilton, B.D. et al., J. Nat. Prod., 1992, 55, 1157, (pmr)
• Huang, C.H.O. et al., J. Nat. Prod., 1986, 49, 665, (isol, deriv)
• Wheeler, N.C. et al., J. Nat. Prod., 1992, 55, 432, (occur)
• Nicolaou, K.C. et al., Angew. Chem., Int. Ed., 1994, 33, 15, (rev)
• Hongjie, Z. et al., Heterocycles, 1994, 38, 975
• Williams, H.J. et al., Tetrahedron, 1993, 49, 6545, (pmr, conformn)
• Slichenmyer, W.J. et al., Anti-Cancer Drugs, 1991, 2, 519, (rev)
• Zhang, H. et al., Yunnan Zhiwu Yanjiu, 1993, 15, 424; CA, 121, 78282e
• Hoke, S.H. et al., J. Nat. Prod., 1994, 57, 277, (ms)
• Horwitz, S.B., Trends Pharmacol. Sci., 1992, 13, 134, (rev)
• Stierle, A. et al., Science (Washington, D.C.), 1993, 260, 214, (isol, ms)
• Suffness, M. et al., Alkaloids (N.Y.), 1985, 25, 10, (rev, pharmacol)
• Potier, P., Chem. Soc. Rev., 1992, 21, 113, (rev)
• Fleming, P.E. et al., J.A.C.S., 1993, 115, 805, (biosynth)
• Blechert, S. et al., Alkaloids (N.Y.), 1990, 39, 195, (rev, pharmacol)
• Rose, W.C., Anti-Cancer Drugs, 1992, 3, 311, (rev)
• Falzone, C.J. et al., Tet. Lett., 1992, 33, 1169, (pmr, cmr)
• Sonnichsen, D.S. et al., Clin. Pharmacokinet., 1994, 27, 256, (rev, pharmacokinet)
• Kingston, D.G.I., Pharmacol. Ther., 1991, 52, 1, (rev, pharmacol)
• Joel, S.P., Chem. Ind. (London), 1994, 172, (rev)
• Kerns, E.H. et al., J. Nat. Prod., 1994, 57, 1391, (ms)
• The Chemistry and Pharmacology of Taxol(R) and its Derivatives, (Ed. Farina, V.), Elsevier, 1995, (book)
• Nicolaou, K.C. et al., Classics in Total Synthesis, Targets, Strategies, Methods, VCH, 1996, 655, (bibl, synth)
• Walker, K. et al., Phytochemistry, 2001, 58, 1-7, (biosynth, rev)
• Taxol: Science and Applications, Ed., Suffness, M, CRC Press, Boca Raton, USA, 1995, (book)
• Heinstein, P. et al., J.C.S. Perkin 1, 1996, 845, (ms)
• Mukaiyama, T. et al., Chem. Eur. J., 1999, 5, 121-161, (Taxol, synth, rev)
• Baloglu, E. et al., J. Nat. Prod., 1999, 62, 1068-1071, (synth)
• Eisenhauer, E.A. et al., Drugs, 1998, 55, 5-30, (pharmacol, rev)
• Fleming, P.E. et al., Pure Appl. Chem., 1994, 66, 2045, (biosynth)
• Rao, K.V., J. Het. Chem., 1997, 34, 675-680, (synth)
• Gimon, M.E. et al., J. Nat. Prod., 1994, 57, 1404, (ms)
• Nicolaou, K.C. et al., J.A.C.S., 1995, 117, 624; 634; 645; 653, (synth)
• Hezari, M. et al., Planta Med., 1997, 63, 291-295, (biosynth, rev)
• Das, B. et al., Indian J. Chem., Sect. B, 1999, 38, 1018-1024, (rev)
• Grothaus, P.G. et al., J. Nat. Prod., 1995, 58, 1003, (immunoassay)
• Rowinsky, E.K. et al., N. Engl. J. Med., 1995, 332, 1004, (use, tox, rev)
• Gao, Q. et al., Tetrahedron, 1996, 52, 2291, (cryst struct)
• Gennari, C. et al., J.O.C., 1997, 62, 4746-4755, (synth)
• Ranson, M. et al., Expert Opin. Invest. Drugs, 1999, 8, 837-848
• Wender, P.A. et al., J.A.C.S., 1997, 119, 2757, (synth)
• Nicolaou, K.C. et al., Nature (London), 1994, 367, 630, (synth)
• Kingston, D.G.I. et al., Tet. Lett., 1994, 35, 4483, (synth)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, TAH775
• Nogales, E. et al., Nature (London), 1995, 375, 424
• Danishefsky, S.J. et al., J.A.C.S., 1996, 118, 2843, (synth)
• Shiina, I. et al., Chem. Lett., 1998, 3-4, (synth)
• Huizing, M.T. et al., J. Chromatogr., B: Biomed. Appl., 1995, 664, 373, (hplc)
• Kusama, H. et al., J.A.C.S., 2000, 122, 3811-3820, (synth)
• Fleming, P.E. et al., J.A.C.S., 1994, 116, 4137, (biosynth)
• Georg, G.I. et al., ACS Symp. Ser., 1995, 583, (book)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 556
• Holton, R.A. et al., J.A.C.S., 1994, 116, 1597; 1599, (synth)
• Gao, Q. et al., Acta Cryst. C, 1995, 51, 295, (cryst struct)
• Vyas, D.M. et al., Prog. Med. Chem., 1995, 32, 289, (rev)
• Danesi, R., et al.: Mol. Pharmacol., 47, 1106 (1984)
• Markman, M., et al.: Expert. Opin. Pharmacother., 3, 755 (1984)
• Letourneau, P.C., et al.: J. Cell Biol., 98, 1355 (1984)
• Manfredi, J.J., et al.: Pharmacol. Ther., 25, 83 (1984)
• Stone, G.W., et al.:
生物活性
PubChem BioAssay
导 航